文献速递胸部肿瘤

TQ-B3139(CT-711)在ALK和ROS1重排晚期非小细胞肺癌患者中的首次人体I期研究

First-in-human phase I study of TQ-B3139 (CT-711) in advanced non-small cell lung cancer patients with ALK and ROS1 rearrangements.
PubMed 文献 · Eur J Cancer · 2022-08-05

这项首次人体I期研究评估了新型ALK酪氨酸激酶抑制剂TQ-B3139在ALK或ROS1阳性晚期非小细胞肺癌患者中的安全性、耐受性、药代动力学和疗效。研究采用3+3设计,剂量从50mg递增至800mg,扩展阶段为200mg每日两次;共纳入63例患者,推荐II期剂量为600mg每日两次,在≥200mg每日两次剂量水平下,TKI初治患者ORR为76.7%,中位PFS为25.2个月。

要点

  • TQ-B3139推荐II期剂量为600mg每日两次,基于安全性和药代动力学数据确定。
  • ≥200mg每日两次剂量下,TKI初治患者ORR为76.7%(33/43),中位PFS为25.2个月(95%CI 11.9-NR)。
  • 可测量脑转移患者颅内ORR为70%(7/10),中位颅内PFS为15.9个月。

核心结论

  • TQ-B3139耐受性良好,在ALK和ROS1阳性晚期非小细胞肺癌患者中展现出有前景的抗肿瘤活性。

研究设计与样本

  • 首次人体I期试验,采用3+3设计,患者接受每日递增剂量TQ-B3139(50-800mg)持续给药,28天为一周期,扩展阶段起始剂量为200mg每日两次。
  • 共纳入63例ALK或ROS1阳性晚期非小细胞肺癌患者。
  • 主要终点为安全性、剂量限制性毒性和推荐II期剂量;次要终点包括药代动力学和抗肿瘤活性。
  • 基线非强制性肿瘤样本被收集并测序。

主要发现

  • 59例(93.4%)患者发生治疗相关不良事件,大多为1-2级呕吐(79.3%)、腹泻(76.1%)或恶心(68.2%)。
  • 600mg每日两次组发生1例(1/6)剂量限制性毒性,800mg每日两次组发生1例(1/3)剂量限制性毒性。
  • 在≥200mg每日两次剂量水平下,TKI初治患者ORR为76.7%(33/43),中位PFS为25.2个月(95%CI 11.9-NR)。
  • 在≥200mg每日两次剂量水平下,TKI经治患者ORR为37.5%(6/16),中位PFS为5.4个月(95%CI 3.6-9.1)。
  • 在≥200mg每日两次剂量水平下,ROS1融合患者ORR为66.7%(2/3);可测量脑转移患者颅内ORR为70%(7/10),中位颅内PFS为15.9个月。

关键数值与推荐

  • 推荐II期剂量为600mg每日两次,基于安全性和药代动力学数据选定。
  • 剂量递增范围为50-800mg每日,扩展阶段起始剂量为200mg每日两次。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: TQ-B3139 is a novel ALK tyrosine kinase inhibitor (TKI) against a broad range of ALK mutations. The aim of this first-in-human phase I trial was to investigate the safety, tolerability, pharmacokinetics, and clinical efficacy of TQ-B3139 in ALK or ROS1 positive advanced NSCLC patients. METHODS: Following a 3 + 3 design, patients received escalating daily dose of TQ-B3139 (50-800 mg) continuously in 28-day cycles. Expansion stage started at dose of 200 mg twice daily (BID). The primary objectives were the safety, dose-limited toxicities (DLT) and recommended phase II dose (RP2D); secondary objectives included pharmacokinetics and antitumor activity. Non-obligatory tumor samples at baseline were collected and sequenced. RESULTS: The study enrolled 63 patients. Fifty-nine (93.4%) patients experienced treatment-related adverse events (TRAEs), mostly grade 1-2 vomiting (79.3%), diarrhea (76.1%) or nausea (68.2%). 1 (1/6) DLT occurred at 600 mg BID and 1 (1/3) at 800 mg BID. Based on safety and pharmacokinetics data, the RP2D was selected as 600 mg BID. At a dose level ≥200 mg BID, the overall response rate (ORR) was 76.7% (33/43), and the median progression free survival (mPFS) was 25.2 months (95%CI 11.9-NR) for TKI-naive patients. For TKI-treated patients, the ORR was 37.5% (6/16), and the mPFS was 5.4 months (95%CI 3.6-9.1). The ORR was 66.7% (2/3) in patients with ROS1 fusion at dose level ≥200 mg BID. In patients with measurable brain metastases, the intracranial ORR was 70% (7/10), with median intracranial PFS of 15.9 months. In TKI-treated patients, variant 3 and TP53 alteration were associated with poor PFS. CONCLUSIONS: TQ-B3139 was well-tolerated and exhibited promising anti-tumor activities in patients with ALK and ROS1 positive advanced NSCLC. CLINICAL TRIAL NUMBER: NCT03099330.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Ma Y, Zhao H, Xue J, et al. First-in-human phase I study of TQ-B3139 (CT-711) in advanced non-small cell lung cancer patients with ALK and ROS1 rearrangements. Eur J Cancer. 2022. PMID: 35940055. doi:10.1016/j.ejca.2022.06.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。